Bolt Biotherapeutics Reports Q3 2026 Results; Advances PRA-216 Phase 2 Program

Bolt Biotherapeutics reported third-quarter 2026 collaboration revenue of zero and a net loss of $4.4 million, compared with revenue of $2.2 million and a net loss of $7.1 million a year earlier. The company completed its acquisition of Prana Therapies and a concurrent $120 million private placemen…